Medistim

Board approval of the 2021 Financial statements for Medistim ASA

(Oslo, 23rd of March 2022) Medistim ASA (OSE: MEDI), a niche market leader

within ultrasound technology with headquarter in Norway, that develops and

commercializes medical equipment for use within cardiac, vascular and transplant

surgery, announces that the Board of Medistim ASA has approved the Financial

Statements for 2021. The Financial Statements are without changes from the

preliminary Financial Statements published on the 25th of February 2022. The

Annual General Meeting will be held on 27th of April 2022.

About Medistim:

Medistim was established in 1984, and has a track record of profitable growth

over the past >15 years. The company is a pioneer within its segment, and

continues to invest in new product development. Medistim has wholly owned

subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark

and Norway, in addition to the about 50 distributors in Europe, Asia, Middle

East, Africa, Canada and South America. For more information, visit the Medistim

home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

AI Terminal